Daiichi Sankyo Enters Europe's Cholesterol Market
Nilemdo and Nustendi Approved
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
